This medication may be part of symptomatic management, applied to provide localized support for symptoms related to inflammatory or irritative states in the anorectal region. The product is relevant across contexts involving heightened discomfort or tension stemming from inflammation.

The medicine is commonly used across conditions presenting with acute or disruptive episodes of localized inflammation. It is relevant for easing symptoms associated with inflamed hemorrhoids, various forms of proctitis, and certain corticosteroid-responsive dermatoses. It may also be applied when appropriate as an adjunct in managing symptoms of chronic ulcerative colitis localized to the rectum.

The medication is commonly used to help with distressing sensory symptoms, including severe anal itching (pruritus ani) and persistent burning. The medication supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load, helping maintain a sense of stability when symptoms are more noticeable.

It is relevant in contexts involving heightened systemic burden, including following anal surgery or for post-irradiation proctitis. The medication supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load in these contexts.

---

Symptom Management Focus

The medication may assist with managing the symptom clusters of swelling, redness, and intense itching associated with anorectal inflammation, contributing to improved day-to-day comfort.

Regulatory References

1. National Library of Medicine (DailyMed)

Official Eligibility: Who Can and Cannot Use Anusol-HC?

Regulatory authorities define strict population eligibility criteria for the use of Anusol-HC (hydrocortisone acetate) rectal preparations, focusing on age, infection status, and reproductive health.

Absolute Contraindications (Must Not Use)

• Patients with a known history of hypersensitivity or allergy to hydrocortisone acetate or any of the components of the product.
• Individuals with existing local primary viral, bacterial, fungal, or tubercular infections in the area of application, including herpes simplex, varicella, and vaccinia.

Age-Group Eligibility

• Adults and the Elderly are the standard eligible populations.
• Use in children under 18 years is not recommended by regulatory bodies (e.g., SmPC).

Restricted Use Populations

• Pregnancy and Lactation: Use is restricted and generally not recommended unless the potential benefit significantly outweighs the possible risk to the fetus or nursing infant (FDA Category C / SmPC restrictions).
• Diagnostic Clearance: The medication must not be used unless an adequate proctologic examination has been performed, especially if rectal bleeding is present.
• Drug Interaction Risk: Patients on co-treatment with strong CYP3A inhibitors (such as ritonavir or cobicistat) are restricted, and this combination should be avoided due to the increased risk of systemic effects.

Interactions with other medicines and products

The interaction profile of Anusol-HC, which contains the corticosteroid Hydrocortisone, is primarily structured around the potential for systemic effects upon absorption. Regulatory documents caution that co-administration with certain medicinal products may result in significant pharmacodynamic or exposure-modifying interactions.

Documented Interaction Patterns

Interacting Substance	Classification Type	Officially Documented Outcome
Potassium-depleting agents (e.g., Diuretics, Amphotericin B)	Pharmacodynamic Reinforcement	May increase the risk of developing hypokalemia (low potassium). Co-use with Amphotericin B has been reported with cardiac enlargement.
Aminoglutethimide	Exposure Modification	May lead to a loss of corticosteroid-induced adrenal suppression, reducing the expected systemic effect.

Interaction-Related Restrictions

The use of corticosteroids is formally contraindicated in the presence of Systemic Fungal Infections. Furthermore, patients receiving immunosuppressant doses of the active ingredient are cautioned to avoid exposure to Live Vaccines due to potential immunological interactions.

Population-Specific Notes

The regulatory information notes that the systemic effect of corticosteroids may be enhanced in individuals with coexisting conditions such as Hypothyroidism or Cirrhosis.

Modulation of Glucocorticoid Receptor Pathways

The active ingredient, hydrocortisone, functions by penetrating target cells and binding to intracellular glucocorticoid receptors (GRs). This ligand-receptor complex translocates into the nucleus, modulating gene transcription. Specifically, the complex represses the genes responsible for producing pro-inflammatory mediators, such as cytokines and chemokines, while inducing the transcription of anti-inflammatory proteins. This action on the genetic level serves to repress the cellular inflammatory cascade within the local microenvironment.

Targeting Vascular and Capillary Dynamics

Hydrocortisone exerts a vasoconstrictive effect on the local microvasculature. It enhances the tone of small blood vessels and contributes to limiting the permeability of capillaries. This action modulates local fluid dynamics by limiting the accumulation of fluid in the tissue. This physiological consequence contributes to modulating the volume of local tissue through altered fluid dynamics.

Suppression of Afferent Signaling

Through the inhibition of pro-inflammatory mediator synthesis, the drug lessens the chemical stimuli that typically activate local sensory nerve endings. By minimizing the release of irritants, the mechanism attenuates the heightened afferent signaling that correlates with pruritic responses.

The administration of prescription Anusol-HC is strictly defined by its dosage form, which dictates the route of application. The medicine is available as a rectal suppository for internal use and a topical cream (2.5%) for external application to the perianal area.

The standard regimen for the rectal suppository, which contains 25 mg of Hydrocortisone acetate, typically involves inserting one suppository twice daily, generally in the morning and at night. For certain severe conditions, the schedule may be increased up to a maximum of 100 mg per day, delivered as four suppositories. The cream is applied thinly to the affected external area, usually two to four times daily.

A core principle of using this local corticosteroid is the restriction on the duration of therapy. Treatment is commonly limited to a short course, such as two weeks for nonspecific proctitis, and should not be used for prolonged periods. Before initiating use, official instructions mandate that an adequate proctologic examination must be completed. Procedural constraints also apply to the manner of application; for instance, the treated area is not to be covered with an occlusive dressing or bandage unless specifically directed. Similarly, when the topical cream is used in the diaper area on pediatric patients, the use of tight-fitting plastic pants or diapers is strictly avoided.

Anusol-HC: Overview of Clinical Evidence

This section summarizes the structure of the clinical research related to the active ingredient in Anusol-HC (Hydrocortisone acetate), focusing strictly on what types of studies have been conducted and the nature of the outcomes examined, without providing clinical advice or interpretations of efficacy.

---

Evidence by Indication

Research on inflamed hemorrhoids primarily consists of short-term Randomized Controlled Trials (RCTs) and comparative studies in adult patients. These studies explored patient-reported outcomes describing perceived discomfort, tracking changes in severity scores for pain, itching, and throbbing, along with physiological outcomes like the cessation of anal bleeding and local swelling reduction. Studies report how symptoms evolved over the defined time intervals of the research.

Evidence for proctitis (including non-specific and post-irradiation forms) is supported by clinical observation studies and comparative trials in adults. Research examined specific measurements of clinical response, such as documenting changes in rectal blood loss, mucus discharge, and mucosal inflammation over treatment phases lasting up to 8 weeks.

Evidence related to the management of severe anal itching (pruritus ani) is mainly drawn from anti-pruritic measurements tracked in trials designed for broader inflammatory anorectal conditions. The research focused on how the quantitative severity score of anal itching changed over short-term periods, typically up to 14 days.

---

Research Gaps and Limitations

A consistent characteristic across the research landscape is that follow-up durations were limited to the short-term, generally corresponding to the acute treatment phase. Consequently, long-term effects are not fully established regarding the durability of a symptomatic response.

Furthermore, for some indications, the volume of randomized trials is lower, resulting in a broader evidence gap. The results apply only to the adult populations studied, and data for certain groups, such as pediatric patients, remain insufficient. Comparative evidence is lacking against the full range of alternative treatment options.

Key Studies & References

1. ANUSOL-HC (hydrocortisone acetate) suppository
2. Hydrocortisone Topical

Common questions about Anusol-HC (FAQ)

Q: Is the hydrocortisone component in Anusol-HC absorbed into the rest of the body?

A: Regulatory documents state that the active ingredient, hydrocortisone acetate, is absorbed into the body’s system. Regulatory studies indicate that in normal subjects, approximately 26% of the drug from the rectal suppository form is absorbed.

Q: What is the difference between Anusol-HC Ointment and Anusol-HC Suppositories?

A: Official product information describes the different forms in relation to their use. The suppository form contains 25 mg of hydrocortisone acetate and is formulated for internal application. Topical forms, like the cream or ointment, are available in strengths such as 1% or 2.5% and are primarily for external or perianal application.

Q: What symptoms indicate a possible serious allergic reaction to Anusol-HC?

A: According to patient information, signs of a serious allergic reaction may include rash, hives, or swelling. These reactions can potentially affect the face, lips, tongue, or throat, and may involve difficulty breathing.

Q: Are there any specific concerns for older adults using Anusol-HC?

A: Official safety information indicates that older adults may experience increased sensitivity to certain systemic effects. These potential effects include bone loss, gastrointestinal bleeding, and changes in mental state or mood, such as confusion.

Q: Is the medication required to be stopped gradually after prolonged use?

A: Prolonged use of any corticosteroid, including the one in Anusol-HC, can lead to the temporary suppression of the body’s natural adrenal gland function. Regulatory information highlights that due to this potential effect, a gradual reduction in dosage (tapering) may be indicated when discontinuing the therapy.

Q: Can the use of Anusol-HC make a person more susceptible to certain types of infections?

A: As an anti-inflammatory steroid, hydrocortisone has properties that can weaken the body's local immune response. This effect may make it harder for the body to fight off or recover from an infection.

Q: What is the description of the theoretical risk of adrenal crisis if Anusol-HC is stopped suddenly after long use?

A: Official documents highlight that prolonged use can lead to adrenal suppression. Stopping the medication abruptly under these conditions carries the theoretical risk of adrenal insufficiency or adrenal crisis, which is described as a medical emergency.

Q: What are the warnings about using Anusol-HC if the person has a current fever or systemic infection?

A: Precautions in official documentation advise using this medication with caution in the presence of a fever or a systemic infection. The same caution applies if the person is dealing with other forms of acute stress or illness.

Q: Can the use of Anusol-HC mask or delay the healing of an underlying infection?

A: Official patient warnings state that due to its anti-inflammatory properties, this medication may cover up or mask the usual signs and symptoms of an existing infection.

Q: What are the different conditions or symptoms that Anusol-HC is officially used to treat?

A: Regulatory documents list several official indications for this medication. These include the management of inflamed hemorrhoids and post-irradiation proctitis. It is also indicated for use as an add-on treatment for chronic ulcerative colitis of the rectum and for severe pruritus ani (anal itching).

Q: Why does Anusol-HC sometimes contain zinc sulfate monohydrate in addition to hydrocortisone?

A: The primary therapeutic component is hydrocortisone, but the full formulation may include excipients like zinc oxide or bismuth compounds. These additional components are included in the formulation to act as mild astringents and protective agents for the local mucous membranes.

Q: How quickly can a person expect to feel relief of symptoms after starting Anusol-HC?

A: Studies and regulatory information suggest that clinical improvement may begin within three to five days of starting therapy. However, it may take a longer period for the full clinical effect to be achieved.

Q: Are there specific signs of a worsening infection that a user should monitor for?

A: Patient safety guidance notes several signs to watch for. These include a sore throat that does not go away, fever, chills, painful urination, or worsening redness or irritation near the application site.

Q: Does having a pre-existing condition like diabetes affect eligibility for Anusol-HC?

A: Official precautions specifically address individuals with diabetes. Hydrocortisone has the potential to raise blood sugar levels, and therefore, closer blood sugar monitoring is indicated during the course of treatment.

Q: What is the guidance for people with high blood pressure or heart problems who use Anusol-HC?

A: The medication should be used with caution in patients who have high blood pressure, heart problems, or congestive heart failure. This is due to the potential for the steroid component to raise blood pressure and cause the body to retain salt and water.

Q: Does Anusol-HC have the potential to cause changes in skin color in the treated area?

A: Adverse reactions officially reported include hypopigmentation. Hypopigmentation is the lightening of the normal skin color in the area where the medication is applied.

Q: What is the official advice for a user whose symptoms do not improve after the prescribed treatment time?

A: Regulatory advice states that if symptoms do not improve, worsen, or if new rectal bleeding occurs, the product should be discontinued and a medical practitioner consulted.

Q: What are the warnings about using Anusol-HC in patients with conditions like peptic ulcers or diverticulitis?

A: Official precautions state that this medication should be used with caution in patients with a history of active or latent peptic ulcers or diverticulitis. This caution is due to the potential for irritation in the gastrointestinal tract.

Q: Are there any published studies examining the use of Anusol-HC in treating ulcerative colitis?

A: Official documents confirm that this medication is indicated for use as an add-on (adjunct) treatment. This use is specifically for chronic ulcerative colitis that involves the rectum.

Q: What types of eye conditions are mentioned as precautions for people using hydrocortisone products?

A: Regulatory precautions are noted for patients with certain pre-existing eye conditions. These include cataracts, glaucoma, and ocular herpes simplex infection.

Q: Is there any official information suggesting dietary changes while using Anusol-HC?

A: Due to the potential for the steroid component to cause the body to retain salt and water, official guidance suggests that a low-salt diet may be advisable. This guidance is particularly relevant for certain patients, such as those with heart failure.

Q: Can the components of Anusol-HC affect a person's bone density or lead to bone-related issues?

A: Official safety information indicates that prolonged use of this medication may increase the risk of developing osteoporosis. This is a concern for bone density and is particularly noted in older adults and children.

Q: Does the medicine have any known interaction with desmopressin?

A: Official interaction information states that co-administration with desmopressin may increase the risk of hyponatremia. Hyponatremia is the term for low sodium levels in the blood.

Q: What is the official information on using Anusol-HC for temporary relief after anorectal surgery?

A: The official product documentation indicates that the topical ointment form of Anusol-HC is specifically indicated for use post-operatively. This is for relief following anorectal surgical procedures.

Q: Is it true that using Anusol-HC can sometimes cause new rectal bleeding to occur?

A: New or persistent rectal bleeding is listed in the regulatory documents as a potential symptom. If this occurs, the official advice is to discontinue use and consult with a medical practitioner.

Storage and Disposal Requirements for Anusol-HC

Anusol-HC (hydrocortisone acetate) must be stored under specific conditions to maintain its effectiveness, as required by regulatory labeling.

Storage Conditions

Requirement	Specific Condition
Temperature	Store at Controlled Room Temperature (20° to 25°C or 68° to 77°F).
Restrictions	Protect from freezing and store away from heat.
Handling	Avoid excessive handling of suppositories, as they are sensitive to temperature.
Child Safety	Keep out of the reach of children. Contact a Poison Control Center immediately in case of accidental ingestion.

Disposal

Unused or expired Anusol-HC should be disposed of according to general government guidance for medications. Do not flush the product down a toilet or pour it into a drain unless instructed to do so by a regulatory authority.